Colorectal Clinical Trials: What is on the Horizon?
- 18 January 2016
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 12 (4) , 525-531
Abstract
Substantial progress has been made in the treatment of colorectal cancer, where more effective therapies have led to improved outcomes in patients with advanced disease. However, the 5-year overall survival rate remains poor. Genomic sequencing has allowed us to understand that colorectal cancer is a heterogeneous disease, where tumor-specific variants affect the prognosis and outcomes in patients. This has shaped the future directions of treatment and the development of clinical trials, including the incorporation of novel targeted therapies and investigations into the role of immunotherapy in colorectal cancer.Keywords
This publication has 58 references indexed in Scilit:
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancerBritish Journal of Cancer, 2011
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E MutationScience Signaling, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008
- Negative Regulation of the Alpha Interferon-Induced Antiviral Response by the Ras/Raf/MEK PathwayJournal of Virology, 2006
- Mutations of the BRAF gene in human cancerNature, 2002